TY - JOUR
T1 - Associations between circulating microRNAs (miR-21, miR-34a, miR-122 and miR-451) and non-alcoholic fatty liver
AU - Yamada, Hiroya
AU - Suzuki, Koji
AU - Ichino, Naohiro
AU - Ando, Yoshitaka
AU - Sawada, Akira
AU - Osakabe, Keisuke
AU - Sugimoto, Keiko
AU - Ohashi, Koji
AU - Teradaira, Ryouji
AU - Inoue, Takashi
AU - Hamajima, Nobuyuki
AU - Hashimoto, Shuji
N1 - Funding Information:
Financial support for this study was provided by the Ministry of Education, Culture, Sports, Science, and Technology of Japan via a grant-in-aid for Scientific Research and a grant-in-aid for Young Scientists Start-up, 2011–2012 (No. 23890226 ).
PY - 2013/9/3
Y1 - 2013/9/3
N2 - Background: In many industrialized countries, non-alcoholic fatty liver disease (NAFLD) is recognized as an important disease that increases the risk of cardiovascular disease, type-2 diabetes, and metabolic syndrome. Most people with NAFLD are asymptomatic, and the disease is discovered incidentally during clinical laboratory tests. Present screening methods for NAFLD use ultrasound, and CT scans that are time-consuming, and a simple screening method for NAFLD is needed. In this study, we investigated whether serum miRNAs are associated with NAFLD and assessed the potential of serum miRNAs as a biomarker for NAFLD. Methods: We assessed intrahepatic fat by ultrasound scan, and the serum levels of five miRNAs (miR-21, miR-34a, miR-122, miR-145, and miR-451), which help regulate cholesterol and fatty acid homeostasis in liver tissue, by real-time PCR in a cross-sectional sample of 403 participants who attended health examinations. Results: Serum levels of miRNAs, miR-21, miR-34a, miR-122, and miR-451 were higher in participants with NAFLD. The serum level of miR-122 was correlated with the severity of liver steatosis. Conclusion: Serum levels of miRNAs, particularly miR-122, may be a useful biomarker for NAFLD.
AB - Background: In many industrialized countries, non-alcoholic fatty liver disease (NAFLD) is recognized as an important disease that increases the risk of cardiovascular disease, type-2 diabetes, and metabolic syndrome. Most people with NAFLD are asymptomatic, and the disease is discovered incidentally during clinical laboratory tests. Present screening methods for NAFLD use ultrasound, and CT scans that are time-consuming, and a simple screening method for NAFLD is needed. In this study, we investigated whether serum miRNAs are associated with NAFLD and assessed the potential of serum miRNAs as a biomarker for NAFLD. Methods: We assessed intrahepatic fat by ultrasound scan, and the serum levels of five miRNAs (miR-21, miR-34a, miR-122, miR-145, and miR-451), which help regulate cholesterol and fatty acid homeostasis in liver tissue, by real-time PCR in a cross-sectional sample of 403 participants who attended health examinations. Results: Serum levels of miRNAs, miR-21, miR-34a, miR-122, and miR-451 were higher in participants with NAFLD. The serum level of miR-122 was correlated with the severity of liver steatosis. Conclusion: Serum levels of miRNAs, particularly miR-122, may be a useful biomarker for NAFLD.
UR - http://www.scopus.com/inward/record.url?scp=84879448114&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84879448114&partnerID=8YFLogxK
U2 - 10.1016/j.cca.2013.05.021
DO - 10.1016/j.cca.2013.05.021
M3 - Article
C2 - 23727030
AN - SCOPUS:84879448114
SN - 0009-8981
VL - 424
SP - 99
EP - 103
JO - Clinica Chimica Acta
JF - Clinica Chimica Acta
ER -
